PureTech entity Celea raises $180 million to move lung disease drug into late stage trial

July 2 (Reuters) - Celea Therapeutics, linked to PureTech Health, on Thursday completed a $180 million financing round for a late-stage trial of its lung disease drug, deupirfenidone, in patients with ...

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis ...

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to IPF ...
BioPharma Dive

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

PureTech spinout lands $180M from investors including RA Capital, Leaps by Bayer

Boston biotech Celea Therapeutics raised $180 million from RA Capital, Leaps by Bayer and others to fund a Phase 3 trial of ...
Nasdaq

PureTech Health Cash Runway Extended

PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in ...
The Business Journals

PureTech names new CEO as biotech seeks funding for two spinouts

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The leadership change comes as ...
Business Wire

PureTech Health: Notice of Results

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December ...